Why the study?
The utilization patterns and cost savings associated with switching from eptacog alfa to eptacog beta as the preferred recombinant factor VIIa product were not well characterized.
Does conversion to eptacog beta from eptacog alfa provide cost savings without adverse outcomes in patients requiring recombinant factor VIIa?
Observational (n=17)
No
Does conversion to eptacog beta from eptacog alfa provide cost savings without adverse outcomes in patients requiring recombinant factor VIIa?
Answers are grounded in this paper and cite their sources.
Institutional conversion from eptacog alfa to eptacog beta was safe, with no thrombotic events, and yielded substantial cost savings.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
George et al. (2025) conducted an observational in Bleeding or peri-procedural management requiring recombinant factor VIIa (n=17). Eptacog beta vs. Eptacog alfa was evaluated on Occurrence of thrombosis, new bleeding events, existing bleeding requiring therapy escalation, and cost savings.
Synapse has enriched 10 related papers. Consider them for comparative context: